Skip to main content
. 2017 Feb 12;7(4):912–925. doi: 10.7150/thno.16615

Figure 8.

Figure 8

Application of Rluc-JEV for antiviral and vaccine efficacy evaluation. (A) Antiviral assay using Ruc-JEV with known antiviral agents. BHK-21 cells were infected with Rluc-JEV at an MOI of 0.01 and incubated with various concentrations of Ribavirin or NITD008. The Rluc activity was measured by Multimode Microplate Reader at 48 h.p.i.. One representative experiment of three is shown. (B) Graphic depiction of assessment of JE vaccine efficacy by using BLI. (C) and (D) BLI of the immunized BALB/c mice or IFNAR-/- mice challenged with Rluc-JEV. Group of BALB/c (C) or IFNAR-/- mice (D) were immunized s.c. with 105 PFU of live JE vaccine SA14-14-2. On 21 days p.i., the immunized mice were challenged with 107 PFU of Rluc-JEV by the i.p. route. BLI of the challenged mice was performed at indicated time points. (E) Survival curve of the immunized IFNAR-/- mice challenged with Rluc-JEV described in (D).